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Abstract
Alcohol is a known carcinogen that may be associated with colorectal cancer. However,
most epidemiologic studies assess alcoholic beverage consumption using self-reported
data, leading to potential exposure misclassification. Biomarkers of alcohol consumption
may provide an alternative, complementary approach that reduces misclassification and
incorporates individual differences in alcohol metabolism. Therefore, we evaluated the
relationship between previously identified alcohol consumption-related metabolites and
colorectal cancer and adenoma using serum metabolomics data from two studies. Data
on colorectal cancer were obtained from a nested case-control study of 502 US adults
(252 cases, 250 controls) within the Prostate, Lung, Colorectal, and Ovarian Cancer
Screening Trial. Data on colorectal adenoma were obtained from a case-control study of
197 US adults (120 cases, 77 controls) from the Navy Colon Adenoma Study. Uncondi-
tional multivariable logistic regression models were fit to calculate odds ratios (OR) and
95% confidence intervals (CI) for eight alcohol consumption-related metabolites identified
in a previous analysis: ethyl glucuronide; 4-androstene-3beta,17beta-diol disulfate 1; 5-
alpha-androstan-3beta,17beta-diol disulfate; 16-hydroxypalmitate; bilirubin (E,Z or Z,E);
cyclo (-leu-pro); dihomo-linoleate (20:2n6); and palmitoleate (16:1n7). We found no clear
association between these alcohol consumption-related metabolites and either endpoint.
However, we did observe an inverse association between cyclo (-leu-pro) and colorectal
adenoma that was only observed in the highest metabolite quantile (OR 4th vs. 1st Quantile =
0.30, 95% CI: 0.12–0.78; P-trend = 0.047), but no association for colorectal cancer. In
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conclusion, there were no adverse associations between alcohol consumption-related
metabolites and colorectal cancer or adenoma.
Introduction
Colorectal cancer ranks third in both cancer incidence and mortality in the US [1,2], with over
132,000 incident cases estimated for 2015 [2]. Colorectal cancer is more common in economi-
cally developed countries, while economically developing countries are seeing rapid increases
in colorectal cancer incidence [3]. Some studies of colorectal cancer risk in migrants from
lower-risk to higher-risk countries have found risk in migrants that approaches that of the host
country [4,5], and that their US-born descendants have higher risks than foreign-born
migrants [6]. These differing patterns may be due to modifiable lifestyle factors [3], including
diet, physical inactivity, obesity, tobacco smoking, and alcohol consumption [7].
Alcoholic beverage consumption has been associated with colorectal cancer in men, and in
many studies women [8], although the association is modest. The summary estimate of a 2010
meta-analysis showed an association with moderate (RR 2 to 3 drinks per day = 1.21, 95% CI: 1.13–
1.28) and heavy drinking (RR 4 drinks per day = 1.52, 95% CI 1.27–1.81) [9]. The evidence is
strongest for heavy drinkers [9–11] and does not appear to vary by alcoholic beverage type,
implicating ethanol as a potential causative agent [11–14]. In observational studies, alcohol
consumption has been associated with each anatomical site of colorectal cancer, including the
proximal colon, distal colon, and rectum [10,11,14]. Less data are available in women. How-
ever, available data indicate similar findings as for men [8,11,14].
Alcoholic beverage consumption has also been associated with higher risk of adenomatous
colorectal polyps [15–19]. Colorectal polyps can be broadly classified into two categories:
hyperplastic polyps, which are typically benign, and adenomatous polyps (adenomas), which
are precursor lesions to colorectal cancer. Although less than 10% of adenomas develop into
colorectal cancer [1], most colorectal cancers develop from adenomas [1,20]. As such, these
findings for alcohol with colorectal cancer and adenoma are complimentary.
Self-reported alcohol consumption data are generally considered to be accurate, and most
epidemiologic studies rely on self-report to measure typical alcohol consumption [21]. How-
ever, self-reported data are subject to reporting error and, subsequently, exposure misclassifica-
tion. Quantity-frequency measures also do not capture binge drinking and atypical drinking
patterns, and this may underestimate total alcohol consumption [22]. In addition, self-reported
alcohol consumption cannot account for individual differences in alcohol metabolism, such as
ethnic differences observed in some Asian populations [23]. Therefore, the use of complemen-
tary measures of alcohol exposure in addition to self-report might be useful in more accurately
estimating alcohol exposure [24]. Alcohol biomarkers, including small-molecule metabolites,
could augment findings from self-report by adding objective measures of exposure and
accounting for individual differences in internal dosing due to individual differences in metab-
olism. Metabolomics, the measurement of small molecules in biofluids, has been shown to be a
useful method in epidemiologic investigations [25,26], with past studies successfully identifying
biomarkers for tobacco smoking and diet, including alcohol [27,28].
In this study we evaluated the association between the following eight biomarkers of alcohol
consumption and colorectal cancer and adenoma: ethyl glucuronide; 4-androstene-3beta,17-
beta-diol disulfate 1; 5-alpha-androstan-3beta,17beta-diol disulfate; 16-hydroxypalmitate; bili-
rubin (E,Z or Z,E); cyclo (-leu-pro); dihomo-linoleate (20:2n6); and palmitoleate (16:1n7).
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These metabolites were selected based on previous serum metabolomics data generated in the
Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO), where they were
found to be associated with total alcoholic beverage consumption based on partial Pearson’s
correlations after Bonferroni correction for multiple comparisons [27]. Using these biomark-
ers, we conducted a nested case-control study of colorectal cancer within the intervention arm
of PLCO (252 cases, 250 controls), as well as a separate case-control study of colorectal ade-
noma (120 cases, 77 controls) in the Navy Colon Adenoma Study.
Materials and Methods
Study design and population
Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO). PLCO is a
population-based randomized controlled trial of the effects of screening on cancer mortality in
the US [29,30]. Over 150,000 participants were enrolled between November 1993 and July
2001. Eligible participants were aged 55–74 years at the time of randomization, had no prior
history of PLCO cancers, and had not had a sigmoidoscopy, colonoscopy, or barium enema
within the three years prior to randomization. Written informed consent was obtained from all
participants. The study was approved by the National Cancer Institute Institutional Review
Board (protocol number OH97-C-N041).
Sigmoidoscopies were conducted at baseline and offered at the end of the third year prior to
December 1998, and at the end of the fifth year beginning in October 1999. Participants with
positive screen tests were referred to their physician for further evaluation.
Within the screening arm of PLCO, a nested case-control study selected participants who
completed baseline risk factor and dietary questionnaires, consented to biospecimen use, had
baseline serum and 6 months or greater of follow-up, had no self-reported history of cancer at
baseline (excepting basal cell carcinoma), had no rare cancers during follow-up, and had no
self-reported Crohn’s disease, ulcerative colitis, familial polyposis, Gardner syndrome, or colo-
rectal polyps. Of these, 255 primary incident colorectal cancer cases and 254 controls were
selected for our study. We further excluded 2 cases and 3 controls with 8 or greater missing
responses on the dietary questionnaire and 1 case and 1 control with extreme caloric consump-
tion (1% or99%). Our final analytic sample for PLCO consisted of 252 cases and 250
controls.
Data on self-reported alcohol consumption were obtained from the baseline questionnaire.
The following categories were chosen a priori based on multiples of a single alcoholic drink,
which provided reasonable numbers of subjects in each category and which are similar to those
in many previous studies of alcohol intake and disease: none,>0 to 1 drink per day,>1 to 3
drinks per day, and>3 drinks per day.
Navy Colon Adenoma Study. The Navy Colon Adenoma Study is a case-control study of
colorectal adenomas which enrolled patients from the General Surgery and Gastroenterology
Clinics at the National Naval Medical Institute in Bethesda, Maryland between April 1994 and
September 1996. Eligible participants were aged 18–74 years, had no history of cancer (except
non-melanoma skin cancer), and resided within 60 miles of Washington D.C. Written
informed consent was obtained from all participants. The study was approved by the Institu-
tional Review Boards at the National Cancer Institute and the National Naval Medical Center
(protocol number OH93-NC-2004).
The study sample for the Navy Colon Adenoma Study has been described in detail elsewhere
[31]. Briefly, 244 cases from a colonoscopy clinic register and 231 controls receiving routine
flexible sigmoidoscopic screening gave informed consent and agreed to participate. We excluded
93 cases for having a history of previous adenomas, 2 cases and 3 controls with implausible
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dietary information, and 3 cases reporting familial adenomatous polyposis. Of these, 129 cases
and 129 controls with height and weight data were selected for metabolic profiling in a previous
analysis [32]. Cases and controls were not matched on fasting status, and preliminary analyses
suggested that fasting status had substantial effects on metabolite concentrations. Therefore, we
further excluded 6 cases and 51 controls who fasted before their blood draw. We then excluded
3 cases and 1 control with missing alcohol consumption data. Our final analytic sample for the
Navy Colon Adenoma Study consisted of 120 cases and 77 controls.
Data on self-reported alcohol consumption were obtained during in-home personal inter-
views conducted approximately 60 to 90 days after endoscopic screening. We categorized alco-
hol consumption into the following categories: none,>0 to 1 drink per day,>1 to 3 drinks per
day, and>3 drinks per day. Non-drinkers who reported ever consuming at least 12 alcoholic
beverages in a year remained categorized as non-drinkers (n = 22).
Outcome assessment
In PLCO, incident cancers were ascertained from the date of randomization (study entry date)
through December 31, 2009. Sigmoidoscopies were conducted at baseline and offered at the
end of the third year prior to December 1998, and at the end of the fifth year beginning in
October 1999. Participants with positive screen tests were referred to their physician for further
evaluation. The 255 first primary incident colorectal cancers diagnosed at least 6 months after
baseline were selected as cases, as were 254 incidence-density sampled subjects who were alive
and cancer free at the time the case was diagnosed and matched by age at randomization (5
year intervals), sex, race, randomization year, and season of blood draw.
In the Navy Colon Adenoma Study, colorectal adenoma cases were diagnosed by colonoscopy
or routine flexible sigmoidoscopy and were histologically confirmed. Controls, selected from
patients without colorectal adenomas at the time of sigmoidoscopy, were frequency matched
(1:1) by age (±5 years) and sex to cases who were screened during the same time period.
Metabolite assessment
In PLCO, non-fasting blood samples were collected at baseline. In the Navy Colon Adenoma
Study, participants provided blood samples at follow-up clinic visits, and were not required to
fast but many participants did. Serum metabolites were assayed by Metabolon Inc, as previ-
ously described [33,34]. The handling and metabolomics analysis of blood samples has also
been described in detail elsewhere [26,27,32]. Samples were run in batches of 30 and blinded to
case status. Cases and matched controls were placed consecutively within the batch. Samples
were analyzed using ultra-high performance liquid-phase chromatography-mass spectrometry
and gas chromatography-mass spectrometry. Metabolites were identified by comparing mass
spectral peaks to a reference library. The relative mass spectral peak intensities for each metab-
olite were batch normalized (relative peak intensity value divided by batch median), log-trans-
formed (natural log), and centered (mean0, standard deviation1). The minimum observed
value was imputed for measurements which failed to reach the detection threshold and the dis-
tributions were centered. Assay precision has previously been studied in detail [26].
A previous serum metabolomics study of PLCO tested correlations between diet and metab-
olites using partial Pearson’s correlations adjusted for age, sex, smoking status (current smok-
ers vs. former/never smokers), and total energy intake (kcal per day) [27]. After Bonferroni
correction for multiple comparisons, eight metabolites were significantly associated with total
alcohol: ethyl glucuronide; 4-androstene-3beta,17beta-diol disulfate 1; 5-alpha-androstan-
3beta,17beta-diol disulfate; 16-hydroxypalmitate; bilirubin (E,Z or Z,E); cyclo (-leu-pro);
dihomo-linoleate (20:2n6); and palmitoleate (16:1n7), and these were used in our study.
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Statistical analysis
We used multivariable unconditional logistic regression to estimate odds ratios (OR) and 95%
confidence intervals (CI) for the relationship between self-reported alcohol and the eight alco-
hol consumption-related metabolites and colorectal cancer (PLCO) and adenoma (Navy Colon
Adenoma Study). The analyses were conducted separately in each study due to differences in
study design, study populations, and data collection methods. All models were adjusted for age
at dietary questionnaire (PLCO) or interview (Navy Colon Adenoma Study), sex, and tobacco
use (never tobacco user, former tobacco user, current tobacco user). Tobacco use included ciga-
rettes, cigars, and pipes.
The eight alcohol consumption-related metabolites were not normally distributed, in part
because values below the detection threshold were assigned the minimum observed value. Five
of the eight metabolites (4-androstene-3beta,17beta-diol disulfate 1; 5-alpha-androstan-
3beta,17beta-diol disulfate; 16-hydroxypalmitate; dihomo-linoleate (20:2n6); palmitoleate
(16:1n7)) were categorized based on the quartile cutpoints among controls. The remaining
three metabolites could not be categorized exactly by quartiles due to the large number of
imputed values. Ethyl glucuronide was categorized as a binary variable (detected, not detected).
Bilirubin (E,Z or Z,E) was categorized by quartile cutpoints in the Navy Colon Adenoma
Study, but in PLCO was categorized into the following percentile groups (27.5,>27.5 to 50.0,
>50.0 to 75.0,>75.0th percentile). Cyclo (-leu-pro) was categorized differently in PLCO
(51.4,>51.4 to 75.0,>75.0th percentile) than in the Navy Colon Adenoma Study (25.4,
>25.4 to 50.0,>50.0 to 75.0,>75.0th percentile).
We also examined bivariate associations between self-reported alcohol consumption and
the eight alcohol consumption-related metabolites previously found to be significantly corre-
lated with total alcohol consumption based on partial Pearson’s correlations adjusted for age,
sex, smoking status, and total energy intake [27]. To account for the non-normal distribution
of the metabolites, we categorized the metabolites based on approximate quartile cutpoints and
then retested their association with alcohol using Fisher’s exact tests. Therefore, the tests we
conducted had lower power than the analysis from which our metabolites were identified.
Because we had eight metabolites identified by their independent correlation with self-
reported alcoholic beverage consumption, we explored their independence and completed a
data reduction for use as a secondary exposure in the association analysis. We used a matrix of
Pearson’s correlation coefficients to assess correlation among the metabolites and to visually
assess whether a subset of metabolites might be used in substitution. A principal component
analysis using varimax rotation was employed as a method to reduce the number of exposure
variables. We retained components based on the eigenvalue-one criterion [35] and those which
cumulatively explained greater than 70% of the variance in the covariance matrix of the eight
alcohol consumption-related metabolites. These meaningful components were then extracted,
scaled by dividing by half the interquartile range, and fit together in a full model, adjusting for
age, sex, and tobacco use.
All analyses were conducted using SAS Version 9.2 TS2M3 (SAS Inc., Cary, North Carolina,
USA).
Results
The sample was predominantly male in both PLCO (cases: 56.4%, controls: 55.6%) and the Navy
Colon Adenoma Study (cases: 75.8%, controls: 74.0%) (Table 1). The mean age was higher in
PLCO (cases: 64.3 years, controls: 64.3 years) than the Navy Colon Adenoma Study (cases: 57.4
years, controls: 57.6 years). The proportion of never tobacco users was similar between PLCO
(cases: 38.0%, controls: 42.0%) and the Navy Colon Adenoma Study (cases: 46.7%, controls:
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42.9%), whereas the proportion of current smokers was higher in PLCO (cases: 47.6%, controls:
49.2%) than in the Navy Colon Adenoma Study (cases: 10.0%, controls: 9.1%).
We examined bivariate associations between demographic variables and self-reported alco-
hol consumption among controls (Table 2). Alcohol consumption was common among con-
trols (PLCO: 80.4%, Navy Colon Adenoma Study: 80.5%) (Table 2). Across the two studies, a
Table 1. Selected Characteristics in 502 US Adults in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) and 197 US
Adults in the Navy Colon Adenoma Study.
Characteristic PLCO Navy Colon Adenoma Study
Case Control Case Control
N (Percent) N (Percent) N (Percent) N (Percent)
Analytic Sample 252 (100.0) 250 (100.0) 120 (100.0) 77 (100.0)
Age (Years), Mean (SD) 64.3 (5.1) 64.3 (5.1) 57.4 (9.1) 57.6 (8.2)
Sex
Female 110 (43.7) 111 (44.4) 29 (24.2) 20 (26.0)
Male 142 (56.4) 139 (55.6) 91 (75.8) 57 (74.0)
Tobacco Use
Never Used Tobacco 95 (38.0) 105 (42.0) 56 (46.7) 33 (42.9)
Former Tobacco User 36 (14.4) 22 (8.8) 52 (43.3) 37 (48.1)
Current Tobacco User 119 (47.6) 123 (49.2) 12 (10.0) 7 (9.1)
Education
High School or Equivalent 83 (32.9) 84 (33.7) 19 (15.8) 4 (5.3)
1 to 3 years College/Vocational 84 (33.3) 75 (30.1) 24 (20.0) 14 (18.4)
College Graduate 42 (16.7) 46 (18.5) 21 (17.5) 17 (22.4)
Post Graduate 43 (17.1) 44 (17.7) 56 (46.7) 41 (54.0)
Race/Ethnicity
White, Non-Hispanic 225 (89.3) 223 (89.2) 102 (85.0) 66 (85.7)
Black, Non-Hispanic 13 (5.2) 13 (5.2) 13 (10.8) 6 (7.8)
Hispanic 3 (1.2) 5 (2.0) 0 (0.0) 2 (2.6)
Other 11 (4.4) 9 (3.6) 5 (4.2) 3 (3.9)
Family History of Colon Cancer
No 210 (84.0) 217 (87.5) 100 (83.3) 67 (88.2)
Yes 33 (13.2) 24 (9.7) 20 (16.7) 9 (11.8)
Possibly 7 (2.8) 7 (2.8) - -
Physical Activity (Hours/Week)
0 to <1 75 (29.8) 78 (31.5) 15 (12.5) 6 (7.8)
1 31 (12.3) 25 (10.1) 6 (5.0) 2 (2.6)
2 47 (18.7) 36 (14.5) 5 (4.2) 4 (5.2)
3 34 (13.5) 34 (13.7) 8 (6.7) 4 (5.2)
4 65 (25.8) 75 (30.2) 86 (71.7) 61 (79.2)
Body Mass Index, Median (IQR) 27.4 (6.6) 26.5 (5.5) 26.5 (4.4) 26.4 (6.0)
Calories, Median (IQR) 1894.6 (1118.7) 1951.5 (954.8) 1487.6 (720.9) 1535.8 (729.5)
Alcohol Consumption (Drinks/Day)
None 54 (21.4) 49 (19.6) 29 (24.2) 15 (19.5)
>0 to 1 139 (55.2) 127 (50.8) 39 (32.5) 27 (35.1)
>1 to 3 32 (12.7) 47 (18.8) 35 (29.2) 25 (32.5)
>3 27 (10.7) 27 (10.8) 17 (14.2) 10 (13.0)
SD Standard Deviation, IQR Interquartile Range.
doi:10.1371/journal.pone.0150962.t001
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Table 2. Selected Characteristics Among Controls by Categories of Alcohol Consumption in 250 US Adults (PLCO) and 77 US Adults.
Characteristic PLCO Navy Colon Adenoma Study
Alcohol Category (Drinks/Day), Na (Percent) P-
Valueb
Alcohol Category (Drinks/Day), Na (Percent) P-
Valueb
None >0 to 1 >1 to 3 >3 None >0 to 1 >1 to 3 >3
Analytic Sample 49 (19.6) 127
(50.8)
47 (18.8) 27 (10.8) - 15 (19.5) 27 (35.1) 25 (32.5) 10 (13.0) -
Age (Years), Mean (SD) 64.2 (5.7) 64.0 (4.9) 65.0 (5.1) 64.9 (5.1) 0.78 56.8 (7.9) 55.3 (9.0) 58.8 (6.8) 62.2 (8.2) 0.14
Sex
Male 26 (18.7) 56 (40.3) 32 (23.0) 25 (18.0) <0.0010 8 (14.0) 19 (33.3) 21 (36.8) 9 (15.8) 0.12
Female 23 (20.7) 71 (64.0) 15 (13.5) 2 (1.8) 7 (35.0) 8 (40.0) 4 (20.0) 1 (5.0)
Tobacco Use
Never Used Tobacco 27 (25.7) 59 (56.2) 15 (14.3) 4 (3.8) 0.0010 9 (27.3) 12 (36.4) 11 (33.3) 1 (3.0) 0.16
Former Tobacco User 21 (17.1) 59 (48.0) 23 (18.7) 20 (16.3) 5 (13.5) 12 (32.4) 11 (29.7) 9 (24.3)
Current Tobacco User 1 (4.6) 9 (40.9) 9 (40.9) 3 (13.6) 1 (14.3) 3 (42.9) 3 (42.9) 0 (0.0)
Education
High School or
Equivalent
23 (27.4) 42 (50.0) 10 (11.9) 9 (10.7) 0.055 1 (25.0) 2 (50.0) 0 (0.0) 1 (25.0) 0.18
1 to 3 years College/
Vocational
16 (21.3) 38 (50.7) 11 (14.7) 10 (13.3) 5 (35.7) 3 (21.4) 4 (28.6) 2 (14.3)
College Graduate 4 (8.7) 22 (47.8) 15 (32.6) 5 (10.9) 5 (29.4) 6 (35.3) 6 (35.3) 0 (0.0)
Post-Graduate 5 (11.4) 25 (56.8) 11 (25.0) 3 (6.8) 4 (9.8) 16 (39.0) 14 (34.2) 7 (17.1)
Race/Ethnicity
White, Non-Hispanic 39 (17.5) 117
(52.5)
43 (19.3) 24 (10.8) 0.31 12 (18.2) 21 (31.8) 24 (36.4) 9 (13.6) 0.60
Black, Non-Hispanic 6 (46.2) 4 (30.8) 2 (15.4) 1 (7.7) 2 (33.3) 2 (33.3) 1 (16.7) 1 (16.7)
Hispanic 1 (20.0) 3 (60.0) 1 (20.0) 0 (0.0) 0 (0.0) 2 (100.0) 0 (0.0) 0 (0.0)
Other 3 (33.3) 3 (33.3) 1 (11.1) 2 (22.2) 1 (33.3) 2 (66.7) 0 (0.0) 0 (0.0)
Family History of Colon
Cancer
No 41 (18.9) 109
(50.2)
42 (19.4) 25 (11.5) 0.88 13 (19.4) 23 (34.3) 22 (32.8) 9 (13.4) 1.00
Yes 5 (20.8) 13 (54.2) 4 (16.7) 2 (8.3) 2 (22.2) 3 (33.3) 3 (33.3) 1 (11.1)
Uncertain 3 (42.9) 3 (42.9) 1 (14.3) 0 (0.0) - - - -
Physical Activity (Hours/
Week)
None 18 (23.1) 38 (48.7) 14 (18.0) 8 (10.3) 0.64 3 (50.0) 0 (0.0) 2 (33.3) 1 (16.7) 0.22
1 7 (28.0) 10 (40.0) 4 (16.0) 4 (16.0) 0 (0.0) 0 (0.0) 2 (100.0) 0 (0.0)
2 9 (25.0) 20 (55.6) 4 (11.1) 3 (8.3) 1 (25.0) 3 (75.0) 0 (0.0) 0 (0.0)
3 3 (8.8) 21 (61.8) 7 (20.6) 3 (8.8) 1 (25.0) 1 (25.0) 2 (50.0) 0 (0.0)
4 11 (14.7) 38 (50.7) 17 (22.7) 9 (12.0) 10 (16.4) 23 (37.7) 19 (31.2) 9 (14.8)
Body Mass Index, Median
(IQR)
26.6 (5.0) 26.5 (6.3) 25.1 (5.3) 27.2 (4.3) 0.43 26.5 (7.5) 25.8 (5.4) 25.8 (4.3) 29.0 (9.3) 0.70
Calories, Median (IQR) 1,614
(984)
1,873
(835)
2,121
(831)
2,339
(972)
<0.0010 1,091
(835)
1,388
(674)
1,553
(467)
2,786
(1,088)
0.0010
a May not sum to total due to missing values.
b Fisher’s exact test (categorical) or Wilcoxon rank sum (continuous).
doi:10.1371/journal.pone.0150962.t002
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similar proportion of control drinkers consumed>3 drinks per day (PLCO: 10.8%, Navy
Colon Adenoma Study: 13.0%). Consuming>3 drinks per day was also more common in
males than females (PLCO: 18.0% vs. 1.8%, Navy Colon Adenoma Study: 15.8% vs. 5.0%).
Among controls, compared with non-drinkers a higher proportion of alcohol drinkers were
ever smokers (PLCO: 61.2% vs. 44.9%, Navy Colon Adenoma Study: 61.3% vs. 40.0%).
We next examined bivariate associations between self-reported alcohol consumption and
the eight alcohol consumption-related metabolites. In PLCO, only five of the eight metabolites
were significantly positively associated with self-reported alcohol consumption: ethyl glucuro-
nide (P< 0.0010); 4-androstene-3beta,17beta-diol disulfate 1 (P< 0.0010); 5-alpha-andro-
stan-3beta,17beta-diol disulfate (P< 0.0010); bilirubin (E,Z or Z,E) (P = 0.0024); and cyclo
(-leu-pro) (P = 0.045) (S1 Table). For each of these five metabolites, a greater proportion of
non-drinkers were distributed in the lowest metabolite quantile, while a higher proportion of
those who drank>3 drinks per day were distributed in the highest metabolite quantile. In the
Navy Colon Adenoma Study, there were only 77 controls, which limited power. None of the
eight metabolites were significantly associated with self-reported alcohol, however a similar
pattern to PLCO was evident for the following alcohol consumption-related metabolites:
4-androstene-3beta,17beta-diol disulfate 1 (P = 0.44); 5-alpha-androstan-3beta,17beta-diol dis-
ulfate (P = 0.079); bilirubin (E,Z or Z,E) (P = 0.65); and cyclo (-leu-pro) (P = 0.12). For these
four metabolites, a greater proportion of non-drinkers were distributed in the lowest metabo-
lite quantile, while a greater proportion of those consuming>1 to 3 drinks per day were dis-
tributed in the highest metabolite quantile.
Because these novel biomarkers are all correlated with self-reported alcoholic beverage con-
sumption, we assessed their independence and to carry out a data reduction to independent
vectors of exposure. We evaluated the Pearson’s correlation coefficients among the eight alco-
hol consumption-related metabolites in a correlation matrix (S2 Table), with absolute values
ranging from 0.028 to 0.88 in PLCO and 0.026 to 0.89 in the Navy Colon Adenoma Study. In
both PLCO and the Navy Colon Adenoma Study, there were two distinct groupings of metabo-
lites with correlation coefficients greater than 0.50: 1) 16-hydroxypalmitate; dihomo-linoleate
(20:2n6); palmitoleate (16:1n7); and 2) 4-androstene-3beta,17beta-diol disulfate 1 and 5-alpha-
androstan-3beta,17beta-diol disulfate. A subsequent principal component analysis identified
three meaningful components. In PLCO, these components cumulatively explained 74.2% of
the variance in the covariance matrix of the eight alcohol consumption-related metabolites.
Individually, components 1, 2, and 3 explained 38.3%, 23.2%, and 12.7% of the variance,
respectively. Similarly, in the Navy Colon Adenoma Study the components cumulatively
explained 75.9% of the variance, with components 1, 2, and 3 respectively explaining 40.2%,
22.5%, and 13.1% of the variance.
Next, we examined associations with our disease endpoints. In fully adjusted models, we
found no association between self-reported typical alcohol consumption and colorectal cancer
(P-trend = 0.25; Table 3) or colorectal adenoma (P-trend = 0.96; Table 4). Likewise, none of the
eight alcohol consumption-related metabolites were significantly associated with colorectal can-
cer, and seven were not significantly associated with colorectal adenoma. However, one metabo-
lite, cyclo (-leu-pro), was significantly associated with colorectal adenoma (P-trend = 0.047).
Compared with relative metabolite levels of cyclo (-leu-pro) among participants in the lowest
quantile, those in the in the second and third quantiles were not significantly associated with
colorectal adenoma (OR 2nd vs. 1st Quantile = 1.11, 95% CI: 0.51–2.44; OR 3rd vs. 1st Quantile = 1.05,
95% CI: 0.47–2.38), whereas peak intensities in the highest quantile were significantly inversely
associated with colorectal adenoma (OR 4th vs. 1st Quantile = 0.30, 95% CI: 0.12–0.78).
Finally, we tested for associations with disease outcome using the uncorrelated eigenvectors
derived from the data reduction analysis. In PLCO, none of the components were associated
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Table 3. Adjusted Odds Ratios and 95%Confidence Intervals for the Association Between Self-Reported Alcohol Consumption/Alcohol Consump-
tion-Related Metabolites and Colorectal Cancer in 502 US Adults (PLCO).
Metabolite Categories Global
P-Value
P-
trenda
Self-Reported Alcohol Consumption Alcohol Category (Drinks/Day)
None >0 to 1 >1 to 3 >3 3 df test
No. Cases/Controls 54/49 139/127 32/47 27/27 0.20 0.25
OR† (95% CI) 1.00 (ref) 0.97 (0.61–1.54) 0.56 (0.31–1.04) 0.81 (0.41–
1.61)
Ethyl Glucuronide 91.43
percentile
>91.43 percentile - - 1 df test
No. Cases/Controls 224/235 28/15 - - 0.059 0.064
OR† (95% CI) 1.00 (ref) 1.87 (0.96–3.62) - -
4-androstene-3beta,17beta-diol disulfate
1
25 percentile >25 to 50 percentile >50 to 75
percentile
>75 percentile 3 df test
No. Cases/Controls 64/63 64/62 57/63 67/62 0.94 0.86
OR† (95% CI) 1.00 (ref) 0.98 (0.58–1.64) 0.86 (0.50–1.49) 0.98 (0.55–
1.73)
5-alpha-androstan-3beta,17beta-diol
disulfate
25 percentile >25 to 50 percentile >50 to 75
percentile
>75 percentile 3 df test
No. Cases/Controls 63/63 64/62 60/63 65/62 0.96 0.67
OR† (95% CI) 1.00 (ref) 0.95 (0.55–1.63) 0.85 (0.44–1.63) 0.91 (0.46–
1.81)
16-Hydroxypalmitate 25 percentile >25 to 50 percentile >50 to 75
percentile
>75 percentile 3 df test
No. Cases/Controls 74/62 70/63 53/62 55/63 0.48 0.14
OR† (95% CI) 1.00 (ref) 0.92 (0.56–1.49) 0.72 (0.44–1.20) 0.73 (0.44–
1.20)
Bilirubin (E,Z or Z,E) 27.49
percentile
>27.49 to 50
percentile
>50 to 75
percentile
>75 percentile 3 df test
No. Cases/Controls 74/69 45/56 79/63 54/62 0.33 0.81
OR† (95% CI) 1.00 (ref) 0.77 (0.46–1.29) 1.19 (0.75–1.91) 0.84 (0.51–
1.39)
Cyclo (-Leu-Pro) 51.39
percentile
>51.39 to 75
percentile
>75 percentile - 2 df test
No. Cases/Controls 138/129 60/59 54/62 - 0.47 0.26
OR† (95% CI) 1.00 (ref) 0.91 (0.59–1.42) 0.75 (0.48–1.18) -
Dihomo-linoleate (20:2n6) 25 percentile >25 to 50 percentile >50 to 75
percentile
>75 percentile 3 df test
No. Cases/Controls 72/62 59/60 68/66 53/62 0.71 0.37
OR† (95% CI) 1.00 (ref) 0.88 (0.53–1.45) 0.97 (0.59–1.58) 0.76 (0.46–
1.26)
Palmitoleate (16:1n7) 25 percentile >25 to 50 percentile >50 to 75
percentile
>75 percentile 3 df test
No. Cases/Controls 69/62 52/56 77/69 54/63 0.63 0.52
OR† (95% CI) 1.00 (ref) 0.87 (0.52–1.45) 1.06 (0.66–1.72) 0.79 (0.47–
1.32)
Abbreviations: CI, Conﬁdence Interval; OR, Odds Ratio.
† Adjusted for age (continuous), sex (binary: female vs. male), and tobacco smoking (categorical: current tobacco user, former tobacco user, never
tobacco user, missing tobacco data).
a Trend was tested using an ordinal variable containing the median value of each alcohol category (self-report) or the median value of the metabolite
categories (alcohol consumption-related metabolites).
doi:10.1371/journal.pone.0150962.t003
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Table 4. Adjusted Odds Ratios and 95%Confidence Intervals for the Association Between Self-Reported Alcohol Consumption/Alcohol Consump-
tion-Related Metabolites and Colorectal Adenoma in 197 US Adults (Navy Colon Adenoma Study).
Metabolite Categories Global
P-Value
P-
trenda
Self-Reported Alcohol Consumption Alcohol Category (Drinks/Day)
None >0 to 1 >1 to 3 >3 3 df test
No. Cases/Controls 29/15 39/27 35/25 17/10 0.86 0.96
OR† (95% CI) 1.00 (ref) 0.75 (0.33–1.72) 0.71 (0.30–1.68) 0.86 (0.29–
2.60)
Ethyl Glucuronide 72.59
percentile
>72.59 percentile - - 1 df test
No. Cases/Controls 98/56 22/21 - - 0.15 0.15
OR† (95% CI) 1.00 (ref) 0.58 (0.28–1.21) - -
4-androstene-3beta,17beta-diol disulfate
1
25 percentile >25 to 50 percentile >50 to 75
percentile
>75 percentile 3 df test
No. Cases/Controls 34/20 26/19 23/19 37/19 0.62 0.70
OR† (95% CI) 1.00 (ref) 0.80 (0.35–1.80) 0.67 (0.29–1.57) 1.14 (0.49–
2.62)
5-alpha-androstan-3beta,17beta-diol
disulfate
25 percentile >25 to 50 percentile >50 to 75
percentile
>75 percentile 3 df test
No. Cases/Controls 35/19 33/20 28/19 24/19 0.68 0.26
OR† (95% CI) 1.00 (ref) 0.79 (0.34–1.86) 0.66 (0.27–1.62) 0.57 (0.22–
1.48)
16-Hydroxypalmitate 25 percentile >25 to 50 percentile >50 to 75
percentile
>75 percentile 3 df test
No. Cases/Controls 37/19 26/20 32/19 25/19 0.69 0.48
OR† (95% CI) 1.00 (ref) 0.66 (0.29–1.49) 0.87 (0.39–1.96) 0.67 (0.29–
1.52)
Bilirubin (E,Z or Z,E) 25 percentile >25 to 50 percentile >50 to 75
percentile
>75 percentile 3 df test
No. Cases/Controls 30/19 24/19 42/20 24/19 0.51 0.79
OR† (95% CI) 1.00 (ref) 0.82 (0.35–1.90) 1.42 (0.63–3.19) 0.85 (0.36–
1.99)
Cyclo (-Leu-Pro) 25.38
percentile
>25.38 to 50
percentile
>50 to 75
percentile
>75 percentile 3 df test
No. Cases/Controls 35/19 40/20 34/18 11/20 0.022 0.047
OR† (95% CI) 1.00 (ref) 1.11 (0.51–2.44) 1.05 (0.47–2.38) 0.30 (0.12–
0.78)
Dihomo-linoleate (20:2n6) 25 percentile >25 to 50 percentile >50 to 75
percentile
>75 percentile 3 df test
No. Cases/Controls 33/19 34/19 32/20 21/19 0.69 0.25
OR† (95% CI) 1.00 (ref) 1.01 (0.45–2.27) 0.91 (0.41–2.02) 0.64 (0.27–
1.48)
Palmitoleate (16:1n7) 25 percentile >25 to 50 percentile >50 to 75
percentile
>75 percentile 3 df test
No. Cases/Controls 38/19 32/19 26/19 24/20 0.65 0.24
OR† (95% CI) 1.00 (ref) 0.86 (0.39–1.90) 0.70 (0.31–1.58) 0.61 (0.27–
1.39)
Abbreviations: CI, Conﬁdence Interval; OR, Odds Ratio.
† Adjusted for age (continuous), sex (binary: female vs. male), and tobacco smoking (categorical: current tobacco user, former tobacco user, never
tobacco user, missing tobacco data).
a Trend was tested using an ordinal variable containing the median value of each alcohol category (self-report) or the median value of the metabolite
categories (alcohol consumption-related metabolites).
doi:10.1371/journal.pone.0150962.t004
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with colorectal cancer (S3 Table). In the Navy Colon Adenoma Study, components 1 and 2
were not significantly associated with colorectal adenoma. However, component 3, which was
loaded heavily from cyclo (-leu-pro), was significantly associated with lower risk for colorectal
adenoma (OR Component 3 = 0.24, 95% CI: 0.06–0.94).
Discussion
In our investigation of alcohol exposure using novel serum biomarkers and risk of colorectal
cancer or colorectal adenoma, we observed little evidence for associations. Our null findings
using these novel serum biomarkers differ from the majority of existing evidence for self-
reported alcoholic beverage use, but are in line with some previous studies that also reported
no significant association between total self-reported alcohol consumption and colorectal can-
cer [36–38] or colorectal adenoma [39–41].
We found one nominally significant inverse association between higher cyclo (-leu-pro)
and lower risk of colorectal adenoma in the Navy Colon Adenoma Study. In PLCO, about half
of control subjects had values below the limit of detection for this metabolite which limited our
ability to test for differences across a spectrum of exposure, but those subjects in the highest
category were at non-significantly reduced risk of colorectal cancer. Cyclo (-leu-pro), a cyclic
dipeptide of leucine and proline, is a byproduct of alcoholic beverage fermentation [42], but
the apparent association with colorectal adenoma should be interpreted with caution given the
modest size of the study and multiple comparisons in the analysis.
Furthermore, because these novel biomarkers must have some degree of correlation, given
that they were selected based on their independent correlation with self-reported alcoholic bev-
erage consumption, we completed a correlation analysis and principal component analysis.
This analysis showed that there were three independent vectors of information among the
eight metabolites that could represent different aspects of alcoholic beverage consumption and
metabolism. These findings could form the basis of future work to better define metabolic pro-
files associated with alcoholic beverage consumption. In the association analysis with these vec-
tors, the one nominally significant association we reported for colorectal adenoma was also
evident in the vector most weighted by cyclo (-leu-pro), but the data reduction did not provide
any other additional insight in our data.
Our investigation of alcohol consumption-related metabolites used an innovative approach
in evaluating the relationship between alcohol consumption and colorectal cancer and ade-
noma. The existing evidence is based primarily on self-reported alcohol consumption and the
strengths of the reported associations are modest [43–46]. Biomarkers of alcohol consumption
can potentially provide certain advantages over self-report by avoiding reporting error, reduc-
ing misclassification, and encompassing individual differences in internal dosing due to indi-
vidual differences in metabolism. For example, in a previous study in PLCO, tobacco
metabolites were found to have a stronger association with colorectal cancer risk than self-
reported tobacco exposure [28].
In addition to the use of novel biomarkers of alcohol exposure, our investigation has other
strengths. First, the study in PLCO was nested within a large prospective study which yielded
252 cases of colorectal cancer with baseline biomarker data. Second, both studies included
detailed information on potential confounders. Our study also included some limitations. First,
the metabolomics platform used for our study provided only relative peak intensities, rather
than metabolite concentrations. Second, the half-lives of the eight alcohol consumption-related
metabolites used in our analysis are unknown, and the time frame of alcohol exposure they
capture is unclear. We lack data on when alcohol was last consumed prior to sample collection,
and we are unsure how these alcohol consumption-related metabolites are influenced by
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lifetime drinking, atypical drinking patterns, and binge drinking. However, future work is in
progress to examine the effects of controlled alcohol ingestion in the Women’s Alcohol Study,
which has been described previously [47]. Third, in PLCO, only five of the eight metabolites
were significantly positively associated with self-reported alcohol consumption, and none were
significant in the Navy Colon Adenoma Study. Fourth, there were relatively few heavy drink-
ers, so we were not powered to evaluate associations at higher levels of alcoholic beverage con-
sumption. Fifth, alcohol may have different associations with different subtypes of colorectal
cancer, but we did not examine these relationships in this study.
In summary, we found no clear evidence for an association between alcohol consumption-
related metabolites and either colorectal cancer or colorectal adenoma. Our data should not be
interpreted as a refutation of studies using self-reported data because these novel biomarkers
represent complementary, not competing, methods of assessing alcoholic beverage consump-
tion. A potential inverse association between cyclo (-leu-pro) and adenoma that was only
observed in the highest metabolite quantile should be evaluated in other data sets.
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